Table 3 Drug-related adverse events during the phase III study
Drug-related adverse events (SOC/PT) | Patients with events, 16/30 (53.3 %) | |
|---|---|---|
Number of patients | Number of events | |
Endocrine disorders | ||
Hyperparathyroidism | 5 | 5 |
Gastrointestinal disorders | ||
Vomiting | 12 | 41 |
Nausea | 12 | 26 |
Abdominal discomfort | 4 | 4 |
Abdominal pain, upper | 3 | 5 |
Diarrhoea | 2 | 7 |
Constipation | 2 | 2 |
Abdominal pain, lower | 1 | 1 |
Faeces, soft | 1 | 1 |
General disorders and administration site conditions | ||
Flank pain | 1 | 9 |
Chest discomfort | 1 | 1 |
Investigations | ||
C-reactive protein increased | 1 | 1 |